{"id":"W4405134861","doi":"10.1016/j.annonc.2024.10.160","title":"135P Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in advanced biliary tract cancer (aBTC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; LG Chem; Kaohsiung Medical University; Eisai; Astellas Pharma; University of Manchester; Servier; Moderna; National Health Research Institutes; Yuhan; Tokyo Cooperative Oncology Group; Halozyme; Ipsen; Kaohsiung Medical University Chung-Ho Memorial Hospital; BeiGene; Mirati Therapeutics; Handok; Eli Lilly and Company; AstraZeneca; Celgene; Pfizer","keywords":"Medicine; Durvalumab; Chemotherapy; Biliary tract cancer; Topaz; Term (time); Oncology; Internal medicine; Cancer; Immunotherapy; Gemcitabine; Astronomy; Geology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00335357,0.0007213472,0.001190463,0.0005575667,0.0002658014,0.00102215,0.0007356117,0.0004929009,0.004243104],"category_scores_gemma":[0.00231036,0.0003325954,0.004125678,0.000747366,0.0003519449,0.0006513955,0.0006069934,0.001826738,0.0003200044],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008608645,"about_ca_system_score_gemma":0.001024474,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003295834,"about_ca_topic_score_gemma":0.007334979,"domain_scores_codex":[0.9988835,0.0007108008,0.00005247481,0.00009609741,0.0001257307,0.0001312479],"domain_scores_gemma":[0.9981434,0.0007351755,0.0004649344,0.0002097927,0.0001067298,0.0003400245],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7572035,0.002229163,0.1062144,0.001349851,0.03293484,0.0003631558,0.0001428402,0.005386622,0.009060079,0.0006797487,0.01407366,0.07036205],"study_design_scores_gemma":[0.2404557,0.08819834,0.6027334,0.0002012407,0.03954789,0.000764632,0.0002412851,0.006017773,0.004724022,0.001501327,0.0155054,0.000109056],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9698377,0.004986431,0.001079006,0.0007317454,0.0001304235,0.000460577,0.01897039,0.0000962179,0.003707655],"genre_scores_gemma":[0.9773058,0.001480473,0.0008490886,0.0006491963,0.0001215344,0.000353849,0.01703801,0.00004807162,0.002153907],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004243104,"threshold_uncertainty_score":0.01773554,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06933144540916644,"score_gpt":0.4118499747647386,"score_spread":0.3425185293555721,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}